ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1524

COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population

Suguni Gallappaththy1, Sarah Ifteqar2 and Amr Edrees3, 1University of Missouri Kansas City, Kansas City, KS, 2UMKC, Kansas City, MO, 3UMKC, Overland Park, KS

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, COVID-19

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Immunological Complications of Therapy Poster (1516–1529)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with autoimmune inflammatory rheumatic disease (AIRD) are at a higher risk for serious infections due to a combination of disease related immune dysfunction and the use of immunosuppressive therapy[1]. With the advent of the COVID-19 vaccination, there is an opportunity to protect this vulnerable patient population. However, there is inadequate data regarding vaccination rates, efficacy and vaccine related adverse events in this unique patient population.

The primary aim of this study is to assess the vaccination rates and adverse events among patients who are on immunosuppressive therapy. The secondary aim was to assess disparities in vaccination rates based on gender, age and ethnicity in patients from an underserved population.

Methods: A retrospective cross-sectional study was conducted from 1st January 2021 to April 30th 2021. Patients aged 18 years and older, who were on immunosuppressive therapy (prednisone >=5mg, conventional and biologic DMARDs) presenting to the rheumatology clinic at an academic medical center, were included. Statistical analysis was done using Chi-square and a p-value of < 0.05 was considered statistically significant.

Results: 376 patients met inclusion criteria. 31.65% (119/376) received atleast one COVID-19 vaccine dose, of whom a majority 28.2% (96/376) were fully vaccinated. 69% patients received the Pfizer and 31% received the Moderna vaccine. Vaccine rates (for atleast 1dose) based on age were variable.18-24 years-41.6%; 25-44 years-16.9%, 45-64 years- 32.6% (58/178) and 65 years and above- 53.7% (36/67) (p< 0.00001). 31.7% (97/306) women and 31.4% (22/70) men receiving atleast one dose. Racial and ethnic differences in vaccinations did not reach statistical significance. 29.5% African Americans (47/159), 28.8% (39/135) Caucasians, 43.6% (17/39) Hispanics, 33.3% (3/9) Asians and 38.2% (13/34) Other received atleast one vaccine dose.

No major adverse events were reported (Table 1). Only 3 vaccinated patients (1.3%) presented to the ED with presumed post vaccination side effects. Complaints included rash, dizziness and headache. 4 vaccinated patients (1.7%) reported a mild exacerbation of their underlying rheumatologic disease. Only 2 vaccinated patients were diagnosed with COVID-19 infection with one patient having received only the 1st dose. The 2nd patient was found to be COVID-19 + within 3 weeks of receiving the 2nd vaccine.

Conclusion: Vaccination rates observed in our patient population was comparable to rates in Missouri (MO)- 31.65% v/s 37.3%(MO) and 28.2% v/s 27.4% (MO) for the 1st and 2nd Covid vaccine doses respectively as of April 30th 2021. Severe adverse events were not seen and the vaccine was well tolerated by our patients. Statistically significant differences were not seen based on gender and ethnicity. Age differences were statistically significant with patients aged 65+ being more likely to get vaccinated, which is likely a reflection of preferential vaccine rollout in more vulnerable populations. Vaccine hesitancy or disparity in access was not seen in our patient population based on preliminary data. Our goal is to reassess the data again in 6 – 12 months to identify any vaccination disparities.


Disclosures: S. Gallappaththy, None; S. Ifteqar, None; A. Edrees, None.

To cite this abstract in AMA style:

Gallappaththy S, Ifteqar S, Edrees A. COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/covid-19-vaccination-rates-and-adverse-events-among-patients-on-immunosuppressive-therapy-in-the-rheumatology-clinic-caring-for-an-underserved-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-vaccination-rates-and-adverse-events-among-patients-on-immunosuppressive-therapy-in-the-rheumatology-clinic-caring-for-an-underserved-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology